Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Chronic Kidney Disease, Receiving Dialysis: later-stage trial registry

1 of 1 indexed Chronic Kidney Disease, Receiving Dialysis trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Chronic Kidney Disease, Receiving Dialysis: 1 US clinical trial tracked, 1 recruiting.

Chronic Kidney Disease, Receiving Dialysis is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Alebund Pharmaceuticals, running 1 of these trials.

Enrollment posture brief

Registry condition chronic-kidney-disease-receiving-dialysis

OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Chronic Kidney Disease, (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Chronic Kidney Disease, Receiving Dialysis

Chronic Kidney Disease, Receiving Dialysis lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Chronic Kidney Disease, Receiving Dialysis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Chronic Kidney Disease, Receiving Dialysis is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

Named interventions

Most-linked intervention names on Chronic Kidney Disease, Receiving Dialysis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

AP301 Low Dose Drug
1 trials
AP301 Drug
1 trials

US sites by state

Facility locations filed on Chronic Kidney Disease, Receiving Dialysis trials. A trial with sites in several states counts in each.

Texas 1 trials
Ohio 1 trials
New York 1 trials
New Mexico 1 trials
Mississippi 1 trials
Louisiana 1 trials
Georgia 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Chronic Kidney Disease, Receiving Dialysis page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Chronic Kidney Disease, Receiving Dialysis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Alebund Pharmaceuticals sponsors the most Chronic Kidney Disease, Receiving Dialysis trials on record, review their full trial history before evaluating a specific study. See Alebund Pharmaceuticals's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Kidney Disease, Receiving Dialysis condition card totals 1 registered trials; most-linked intervention AP301 Low Dose; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.